CRISM Therapeutics Corporation (LON:CRTX)
9.62p-3.80%
Spriggl Score: Poor— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Pre-revenue brain cancer biotech; first patients treated this summer, but trial failure risks everything.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the del…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £7.9M
Recent dividends
- 1 Jun 2023288p
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across CRISM Therapeutics Corporation and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free